Restoring thromboangioplasticity in antiphospholipid syndrome by developing recombinant proteins that counteract harmful anti-annexin V antibodies.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Designing synthetic antigens that reprogram allergic immune memory toward durable, healthy responses — moving precision allergy vaccines toward the clinic.
Building AI-powered digital avatars that simulate each patient's immune system to predict therapy response and accelerate precision immunotherapy development.
Characterizing a newly discovered IgE receptor to develop it into a drug that clears circulating IgE and treats allergic diseases.
Developing T cell-redirecting bispecific antibodies to selectively eliminate tuft cells and break the cycle of Type 2 inflammation in CRSwNP.
Using spatial transcriptomics to map distinct HS disease endotypes and identify targeted therapeutic strategies for this underserved inflammatory skin disease.
Identifying DNA methylation signatures in blood and urine as non-invasive biomarkers to classify lupus nephritis and guide treatment without repeated biopsies.
Engineering TET2-deficient beta cells that resist autoimmune attack to create replacement cell therapies for type 1 diabetes.
